10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

UBXN1 Blocking Peptide (Center)

Synthetic peptide
Catalog # BP5360c

Specification

UBXN1 Blocking Peptide (Center) - Product Information

Primary Accession	Q04323
Other Accession	Q922Y1, Q32KW2, NP_056937.2

UBXN1 Blocking Peptide (Center) - Additional Information

Gene ID 51035

Other Names
UBX domain-containing protein 1, SAPK substrate protein 1, UBA/UBX 333 kDa protein, UBXN1, SAKS1

Target/Specificity
The synthetic peptide sequence is selected from aa 165-178 of HUMAN UBXN1

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

UBXN1 Blocking Peptide (Center) - Protein Information

Name UBXN1

Synonyms SAKS1

Function
Ubiquitin-binding protein that plays a role in the modulation of innate immune response. Blocks both the RIG-I-like receptors (RLR) and NF-kappa-B pathways. Following viral infection, UBXN1 is induced and recruited to the RLR component MAVS. In turn, interferes with MAVS oligomerization, and disrupts the MAVS/TRAF3/TRAF6 signalosome. This function probably serves as a brake to prevent excessive RLR signaling (PubMed:23545497). Interferes with the TNFalpha-triggered NF-kappa-B pathway by interacting with cellular inhibitors of apoptosis proteins (cIAPs) and thereby inhibiting their recruitment to TNFR1 (PubMed:25681446). Also prevents the activation of NF-kappa-B by associating with CUL1 and thus inhibiting NF-kappa-B inhibitor alpha/NFKBIA degradation that remains bound to NF-kappa-B (PubMed:<a href="http://www.uniprot.org/citations/28152074"

target="_blank">28152074). Interacts with the BRCA1-BARD1 heterodimer and regulates its activity. Specifically binds 'Lys-6'-linked polyubiquitin chains. Interaction with autoubiquitinated BRCA1 leads to the inhibition of the E3 ubiquitin-protein ligase activity of the BRCA1- BARD1 heterodimer (PubMed:20351172). Component of a complex required to couple deglycosylation and proteasome-mediated degradation of misfolded proteins in the endoplasmic reticulum that are retrotranslocated in the cytosol.

Cellular Location
Cytoplasm.

UBXN1 Blocking Peptide (Center) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

UBXN1 Blocking Peptide (Center) - Images

UBXN1 Blocking Peptide (Center) - References

Ishibashi, T., et al. J. Biochem. 137(5):617-623(2005)
Barrios-Rodiles, M., et al. Science 307(5715):1621-1625(2005)
McNeill, H., et al. Biochem. J. 384 (PT 2), 391-400 (2004) :
Puente, X.S., et al. Nat. Rev. Genet. 4(7):544-558(2003)
Hoja, M.R., et al. Exp. Cell Res. 259(1):239-246(2000)